<DOC>
	<DOCNO>NCT02287402</DOCNO>
	<brief_summary>The purpose open-label study evaluate efficacy safety AO-128 ( Voglibose ) 0.6 mg/day patient impair glucose tolerance ( IGT ) non-responsive diet therapy exercise therapy , follow progress end treatment patient assessed normoglycemic .</brief_summary>
	<brief_title>Postmarketing Clinical Study AO-128</brief_title>
	<detailed_description>The Î±-glucosidase inhibitor voglibose develop Takeda Pharmaceutical Co. Ltd one commonly used oral antidiabetic agent Japan . Voglibose use first-line treatment improvement postprandial hyperglycemia diabetic patient inadequate response diet exercise therapy add-on treatment oral antidiabetic drug insulin . In 2009 , voglibose approve Japan management prediabetes ( IGT ) . This study single-group , multi-center , open-label study . The study period consist screening period 1 week less , treatment period 96 week , follow-up period 48 week . However , patient assess type 2 diabetes mellitus normoglycemia , treatment period end , assess normoglycemic proceed follow-up . Follow-up also terminate patient assessed IGT type 2 diabetes mellitus follow-up .</detailed_description>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>1 . Patients diet therapy exercise therapy 3 6 month prior start screening , baseline ( fast ) plasma glucose &lt; 126 mg/dL 2hour plasma glucose 140 199 mg/dL ( revise WHO criteria ) 75 g oral glucose tolerance test ( OGTT ) screen period 2 . Patients meet 1 4 : 1 ) Comorbid hypertension high normal blood pressure 2 ) Comorbid dyslipidemia 3 ) Comorbid obesity 4 ) Patients seconddegree family history type 2 diabetes mellitus 3 . Patients HbA1c &lt; 6.5 % screening period 4 . Male female patient least 20 year age time inform consent obtain 5 . Treatment category : Outpatient 1 . Patients previously diagnose diabetes mellitus . 2 . Patients apparent impaired glucose metabolism disease condition potentially involve impair glucose metabolism . 3 . Patients serious hepatic impairment . 4 . Patients serious renal impairment . 5 . Patients serious cardiac , cerebrovascular , pancreatic , hematologic , disease . 6 . Patients history intestinal obstruction history laparotomy within 6 month ( 24 week ) start screen .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>